Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Latest Sofinnova Stories

2011-03-07 05:00:00

RESEARCH TRIANGLE PARK, N.C., March 7, 2011 /PRNewswire/ -- Aerie Pharmaceuticals, Inc, a biotechnology company focused on the discovery and development of medical innovations in ophthalmology, today announced the closing of a $30 million Series B financing. Clarus Ventures and Sofinnova Ventures co-led the round, with participation from Osage University Partners, and existing investors Alta Partners and TPG Biotech. Aerie expects to use proceeds from this financing to fund continued...

2010-12-16 07:30:00

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2010 /PRNewswire/ -- Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced the receipt of a $4.0 million milestone payment from Pfizer Inc. under the terms of the collaboration agreement for the development of improved recombinant human Factor VIIa variants for the treatment of hemophilia and other bleeding disorders. "We are very encouraged by the progress made to date in our...

2010-10-12 07:00:00

CHAPEL HILL, N.C., Oct. 12 /PRNewswire/ -- Cempra Pharmaceuticals announced that Richard Kent, M.D., a partner at Intersouth Partners, has been appointed to Cempra's board of directors. Dr. Kent will replace Garheng Kong, M.D., Ph.D., M.B.A., as Intersouth's representative on the board. Dr. Kong, who has recently taken a position as a general partner at Sofinnova Ventures, will continue as Cempra's chairman of the board. Dr. Kent brings extensive pharmaceutical management and drug...

2010-09-15 02:59:00

LUXEMBOURG, September 15, 2010 /PRNewswire/ -- Creabilis SA, a clinical stage European biotechnology company addressing significant unmet medical needs in dermatological diseases, today announced the appointment of George F. Horner III as its Chairman. Mr Horner brings to Creabilis an unrivalled track record in building successful biotech businesses that have generated significant value for their shareholders. Mr Horner has over 40 years industry experience gained with both biotech...

2010-09-08 07:10:00

MENLO PARK, Calif., Sept. 8 /PRNewswire/ -- Sofinnova Ventures, a venture capital firm based in Silicon Valley, today announced that Garheng Kong, M.D., Ph.D. has joined the firm as General Partner. He will actively invest in biopharmaceutical companies from the firm's current fund, SVP VII. Up until joining Sofinnova, Kong was a General Partner at Intersouth Partners, where he has been for the past ten years. He was the founding investor of Cellective Therapeutics, a Sofinnova Ventures...

2010-07-01 01:27:00

PARIS, July 1, 2010 /PRNewswire/ -- - EUR 13.7m Second Round Funding Sofinnova Partners, acting as a leading investor, Gimv and Amundi Private Equity Funds announced today their investment in McPhy Energy, together with the historic investors in a second round of funding worth EUR 13.7m. The funds will be used towards the global expansion of McPhy Energy and the further industrialisation and commercialisation of its products. McPhy Energy is an innovative French company...

2010-05-04 03:00:00

MARSEILLE, France, May 4, 2010 /PRNewswire/ -- WYPLAY SAS, a pioneer in the development of the High-Definition Media Center, today announced it has closed a 9 million euro third round of financing. Amundi Private Equity Funds, who led this 3rd round, was joined by A Plus Finance, Elaia Partners and Sofinnova Partners, Wyplay's second round lead investors reflecting their continued confidence in the company. Together with the two previous investment rounds totaling EUR14 million, the...

2010-02-23 05:00:00

LA JOLLA, Calif., Feb. 23 /PRNewswire/ -- Intellikine, Inc., a leader in the development of drugs against the PI3K/mTOR pathway, today announced that William R. Rohn has joined the company's board of directors. Mr. Rohn has over 30 years of management experience in the biotechnology and pharmaceutical industry, including more than 10 years in executive management positions at IDEC Pharmaceuticals and Biogen Idec, where he served as Chief Operating Officer until his retirement in 2005. He...

2010-01-08 07:33:00

CAMBRIDGE, England, January 8 /PRNewswire/ -- Crescendo Biologics ("Crescendo") today announces the appointment of Clive Dix as Chairman. Dr Dix will work closely with Mike Romanos, Chief Scientific Officer of Crescendo, to drive the development of the Company and its proprietary antibody fragment technologies following the recent GBP4.5 million seed round fundraising. Dr Dix has an exceptional track record established over more than 20 years in the pharmaceutical and biotechnology...

2009-10-26 06:00:00

PRINCETON, NJ, Oct. 26 /PRNewswire/ - DNP Green Technology is pleased to announce that a syndicate led by Sofinnova Partners and including Mitsui & Co. Venture Partners, Samsung Ventures Investment Corporation, the Cliffton Group and AquaRIMCO has completed a US$12M equity investment in the company. All participants with the exception of AquaRIMCO are new investors. DNP Green is a late stage bio-materials company that will begin selling bio-based succinic acid in 2009 through its Bioamber...